SCHEMBL1502485

SCHEMBL1502485

COCCc1cc2c(-n3c(S)nnc3-c3ccc(O)cc3O)cccc2[nH]1

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 6/20 0.38
HSP90AB1 P08238 1/20 0.38
GAA P10253 3/20 0.34
MGAM O43451 2/20 0.34
SI P14410 2/20 0.34
MGAM2 Q2M2H8 2/20 0.34
CDK4 P11802 1/20 0.33
CCNA2 P20248 1/20 0.33
CCND1 P24385 1/20 0.33
CDK2 P24941 1/20 0.33
CCND3 P30281 1/20 0.33
MTNR1A P48039 2/20 0.31
MTNR1B P49286 2/20 0.31
KDM4E B2RXH2 1/20 0.31
MAPT P10636 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
HTR7 P34969 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL443459 0.80 GAA (0.34) HSP90AA1HSP90AB1GAAMGAMSI
SCHEMBL14184044 0.78 HSP90AA1 (0.46) HSP90AA1HSP90AB1GAAKDM4EMAPT
SCHEMBL420051 0.76 HSP90AA1 (0.37) HSP90AA1HSP90AB1GAA
SCHEMBL2596685 0.76 HSP90AA1 (0.35) HSP90AA1GAAMTNR1AMTNR1BKDM4E
SCHEMBL1502369 0.76 FLT3 (0.37) HSP90AA1GAAMGAMSIMGAM2
SCHEMBL930591 0.76 HSP90AA1 (0.57) HSP90AA1HSP90AB1GAAMTNR1AMTNR1B
SCHEMBL442579 0.76 HSP90AA1 (0.38) HSP90AA1HSP90AB1
SCHEMBL445190 0.75 HSP90AA1 (0.37) HSP90AA1GAAMGAMSIMGAM2
SCHEMBL931155 0.74 GAA (0.41) HSP90AA1HSP90AB1GAAKDM4EMAPT
SCHEMBL931757 0.74 HSP90AA1 (0.44) HSP90AA1HSP90AB1GAAKDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2678014-A2 PROSTATE CANCER THERAPY WITH HSP90 INHIBITORY COMPOUNDS Synta Pharmaceuticals Corp. (US) 2014-01-01 EP disclosed
WO-2012141796-A2 PROSTATE CANCER THERAPY WITH HSP90 INHIBITORY COMPOUNDS SYNTA PHARMACEUTICALS CORP. (US) 2012-10-18 WO disclosed
EP-2298748-A2 Triazole compounds that modulate HSP90 activity Synta Pharmaceuticals Corp. (US) 2011-03-23 EP disclosed